NCT00083707View on ClinicalTrials.gov

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

January 31, 1999

Study Completion Date

February 28, 2003

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG

Thalidomide

Trial Locations (1)

72205

University of Arkansas for Medical Sciences/MIRT, Little Rock

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of Arkansas

OTHER